Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.
Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...
Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...
A phase one study shows personalised T cell activation induced durable immune responses with manageable toxicity in patients with chronic lymphocytic leukaemia receiving targeted therapy.
“RedTail is a major leap forward in the delivery of genetic medicine via an engineered virus,” said Eric Poma, PhD, Chief Executive Officer of Calidi. “It is able to avoid immune clearance allowing ...
News-Medical.Net on MSN
Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study
By Hugo Francisco de Souza A novel CAR-T cell approach targets amyloid plaques in preclinical Alzheimer models, raising the ...
The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...
AZoLifeSciences on MSN
Engineered CD4 CAR T cells reduce amyloid plaques in Alzheimer’s
Findings suggest engineered CD4+ T cells can modify Alzheimer's pathology and improve CNS immune responses, highlighting a novel therapeutic approach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results